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http://dx.doi.org/10.1016/j.kjms.201Abstract We report the case of a 38-year-old man who developed vanishing bile duct syn-
drome in association with Hodgkin’s lymphoma. He was noted to have cervical lymphadenop-
athy and marked elevation of total serum bilirubin at diagnosis. He achieved complete
remission with normalization of serum bilirubin after eight courses of Adriamycin, bleomycin,
vinblastine, and dacarbazine chemotherapy followed with autologous hematopoietic cell
transplantation. Consecutive liver biopsies performed at diagnosis and at the stage of com-
plete remission revealed the disappearance and regeneration of interlobular bile ducts,
respectively. Our case provides pathological evidence that Hodgkin’s lymphoma-related van-
ishing bile duct syndrome is a reversible bile duct injury disease. Bilirubin is a reliable serum
marker to monitor the treatment response of these cases. The mechanism to develop hyper-
bilirubinemia with vanishing bile duct in such a case of Hodgkin’s lymphoma remains to be
studied. A literature review was carried out.
Copyright ª 2013, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.of HematologyeOncology,
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Jaundice related to Hodgkin’s lymphoma (HL) has been
reported to occur in 3e13% patients [1,2]. The common
causes of abnormal liver function in these patients include
extrahepatic bile duct obstruction or hepatic infiltration byed by Elsevier Taiwan LLC. All rights reserved.
HL-related vanishing bile duct syndrome 637lymphoma cells, viral hepatitis, or complications of
chemotherapeutic treatment [2]. A rare paraneoplastic
syndrome in association with HL, called vanishing bile duct
syndrome (VBDS), was first described in 1993 by Hubscher
et al. [3]. This syndrome presents with severe icterus and
hepatic abnormalities as a result of loss of normal bile duct.
The mechanism of hyperbilirubinemia in HL-related VBDS
and its resolution remain unclear. Few studies have
described the pathogenesis of VBDS in such a case. Our case
provides evidence of ductopenia at diagnosis and its reso-
lution postchemotherapy by serial liver biopsies. A litera-
ture review of HL-related VBDS was carried out.Case report
A 38-year-old man was admitted to our ward with com-
plaints of abdominal pain and jaundice for 1 week. Past
history showed that he had dyslipidemia and depressive
disorder and had been under Bupropion treatment. TheFigure 1. Portal tract devoid of bile duct, as highlighted by a lack
on pretreatment liver biopsy. Normal portal tract with regeneration
on post-treatment liver biopsy. Parallel hepatic artery branches (r
inflammatory activity and no fibrosis with steatohepatitis and chol
tract. (HE, original magnification: 400). (B) Grade II portal and lob
(HE, original magnification: 400). (C) Focal decrease numbers o
400). (D) Increased numbers of interlobular bile ducts in portal t
Arrows show interlobular bile ducts (CK 19, original magnification:associated symptoms and signs included nausea sensation,
watery diarrhea, and fever. He had consumed some alcohol
over recent days, and had travelled to China and Japan
recently. He denied receiving blood transfusion, intrave-
nous drug abuse, high-risk sexual behavior, or exposure to
drugs or viral hepatitis. Physical examination showed
icteric sclera, right neck lymph node swelling, and mild
upper abdomen tenderness. Laboratory tests revealed
bilirubin (total/direct), 14.8/9.39 mg/dL; alanine trans-
aminase (ALT), 181 IU/L; aspartate aminotransferase (AST),
53 IU/L; alkaline phosphatase, 155 IU/L; and gamma-
glutamyl transferase, 317 IU/L. The hemogram was
normal. The virology tests were negative for hepatitis A
virus, hepatitis B virus, hepatitis C virus, EpsteineBarr
virus, herpes simplex virus, human immunodeficiency virus,
and cytomegalovirus. Immunology tests revealed normal
levels of b2-microglobulin, complement component 3 (C3),
complement component 4 (C4), and immunoglobulin, and
the test was negative for antinuclear antibody. Cerulo-
plasmin level was normal. Neck computed tomography (CT)of HE stain- and CK 19 stain-positive structure within the tract
bile duct was present at the periphery of tract (white arrows)
ed arrows) were demonstrated. (A) Grade I portal and lobular
estasis. Loss of normal interlobular bile duct around the portal
ular inflammatory activity. Arrows show interlobular bile ducts.
f bile duct in portal tract area (CK 19, original magnification:
ract area demonstrated by CK 19 immunohistochemical stain.
400). CK Z cytokeratin; HE Z hematoxylin and eosin.
Serial changes of liver biochemical levels in response to clinical treatments
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Figure 2. Serial changes in liver biochemical levels in response to clinical treatments. The patient was treated with eight cycles
of ABVD regimen chemotherapy (a black arrow for each cycle) from Week 4 to Week 32 after diagnosis of Hodgkin’s lymphoma. The
patient received autologous hematopoietic cell transplantation in Week 55 (open arrow). Liver biochemical levels normalized in
Week 70 after clinical treatment. ABVD Z adriamycin, bleomycin, vinblastine, and dacarbazine; ALP Z alkaline phosphatase;
AST Z aspartate aminotransferase; Bil Z bilirubin.
638 K.-M. Wong et al.scan showed enlarged lymph nodes over the right jug-
ulodigastric, posterior cervical, and supraclavicular areas.
Abdominal CT scan revealed normal intrahepatic biliary
duct and unremarkable intra-abdominal lymphadenopathy.
Positron emission tomographyecomputed tomography
(PET-CT) scan revealed involvement of cervical regions,
mediastinum, and bilateral axillary basins. Suspicious
spleen and bone marrow involvement were also noted.
Neck lymph node biopsy was performed, and the pathology
revealed classical HL with mixed cellular subtype. Bone
marrow biopsy was found negative for lymphoma
involvement.
Due to persistent jaundice, a liver biopsy was carried
out; the pathology showed cholestasis with absent or
focally decreased numbers of bile ductules in the portal
tract areas in the whole specimen (Fig. 1A and C) rather
than proliferative ones and no Hodgkin cell was identified,
which addressed the possibility of HL-related VBDS. After
diagnosis of HL Stage IIA, the patient was treated with
standard adriamycin, bleomycin, vinblastine, and dacar-
bazine (ABVD) regimen chemotherapy biweekly. The
dosage of chemotherapy was adjusted according to the
reference for Truven Heath Analytics Micromedex version
1.0 (Healthcare Series) due to hepatic insufficiency. A total
of eight courses (4 cycles) of ABVD chemotherapy were
given over 28 weeks. The patient’s total bilirubin level
returned to nearly normal on Week 28 (Fig. 2). Liver biopsy
repeated on Week 36 revealed regeneration of interlobular
bile ducts (Fig 1B and D). Three months after chemotherapy
had been completed, the patient received peripheral blood
stem cell mobilization with cyclophosphamide 4 g/m2 fol-
lowed by peripheral blood stem cell harvest. Autologous
hematopoietic cell transplantation with BEAM (Bischlor-
oethylnitrosourea (BCNU), etoposide, cytosine arabinoside,
and melphalan) conditioning regimen was carried out 3
months after peripheral blood stem cell harvest. Total nu-
clear cell count 6.42  108/kg and CD34 count 1.67  106/
kg body weight were administered during the autologous
hematopoietic cell transplantation. Full engraftment wasreached on Day 19 after autologous hematopoietic cell
transplantation. The patient has maintained remission
state up to the time of writing (more than 7 months) and is
regularly followed up at our outpatient service.Discussion
VBDS is a common pathologic manifestation resulting from
various etiologies such as autoimmune disease, medica-
tions, infections, neoplastic disorders, and genetic abnor-
malities [4]. HL-related VBDS was first reported by
Hubscher et al. [3] in three Hodgkin disease patients with
intrahepatic cholestasis and ductopenia in 1993. Ductope-
nia was defined as a decreasing of bile duct numbers in
pathology. The bile duct numbers were determined as a
percentage by counting the number of portal tracts with
ducts and dividing it by the total number of portal tracts
present. Following Hubscher et al’s work, we performed a
literature search in PubMed database using “vanishing bile
duct syndrome”, “Hodgkin’s lymphoma”, and “ductopenia”
as keywords. The search yielded a total of 23 HL-related
VBDS cases from 1993 to 2011 (Table 1) [3e19], which
included both English and non-English publications.
An overview of the clinical presentations of the afore-
mentioned 23 patients is given in Table 2. Patients tended
to be young with a mean age of 28 years (range, 3.5e54
years), and there was a male predominance (maleefemale
ratio, 3.6:1). All patients had jaundice (100%) and pruritus
(100%). Other common symptoms and signs were weight
loss (93%), night sweats (78%), and fever (70%). Most pa-
tients had palpable neck lymphadenopathy (84%), whereas
fewer patients presented with hepatomegaly (50%) and
splenomegaly (33%).
Total bilirubin levels were elevated in all cases, with a
mean of 305 mmol/L (range, 34e856 mmol/L). Serum alka-
line phosphatase levels were increased markedly in many
cases, with a mean of 960 IU/L (range, 155e5724 IU/L). AST
levels seldom exceeded 200 IU/L in those patients, with a
Table 1 Review cases of Hodgkin’s lymphoma-related vanishing bile duct syndrome.
Ref Year Stage Tx Age Sex Pretreatment Post-treatment Outcome
Biopsy Bil
(mmol/L)
AST
(IU/L)
ALP
(IU/L)
Biopsy Bil
(mmol/L)
AST
(IU/L)
ALP
(IU/L)
[3] 1993 IA CRS 44 M Ductopenia 300 100 210 HD 700 300 600 D: liver failure
[3] 1993 NR C 26 M Nil 400 100 200 Ductopenia 800 80 100 D: sepsis
[3] 1993 IIB CS 37 F Ductopenia NR NR NR NIL NR NR NR D: sepsis
[10] 1997 IIIB C 21 F Ductopenia 245 108 198 DR 11 193 469 Alive
[8] 1997 IIA CRS 3.5 M Ductopenia 856 100 500 Ductopenia 682 300 700 D: liver failure
[13] 1997 IB CS 5 M Ductopenia NR 67 998 NIL NR NR NR D: liver failure
[14] 1998 IIIB CS 27 F Ductopenia 399 83 NR NIL 646 98 NR Alive
[14] 1998 IIIB CS 50 F Ductopenia 370 78 NR NIL 430 102 NR D: sepsis
[15] 2000 IA CS 38 M Ductopenia 34 203 2041 NIL 46 210 7970 D: liver failure
[7] 2000 IIIB C 54 M Ductopenia 51 NR 138 Ductopenia NR NR 360 Alive
[5] 2001 IIIB CS 3.5 M Nil 105 55 210 Ductopenia NR NR NR D: liver failure
[9] 2002 IIA CRS 28 F Ductopenia 559 68 619 Ductopenia 653 NR 2925 D: HD
[9] 2002 IIA CRS 23 M Ductopenia NR NR NR Ductopenia 459 174 2481 Alive
[6] 2004 IIA R 43 M Nil NR NR NR Ductopenia 215 40 348 Alive
[16] 2004 IIIB C 46 M Ductopenia 266 86 384 NIL 300 180 1200 D: sepsis
[11] 2005 NR CS 17 M Ductopenia 57 120 5724 DR 4.8 56 1084 Alive
[17] 2006 IIIA NT 46 M Ductopenia 217 36 170 NIL NR NR NR D: sepsis
[12] 2007 IIA CRS 22 M Ductopenia 444 134 236 NIL 27 40 117 Alive
[18] 2007 IIIB C 17 M Ductopenia 473 148 964 NIL 13 46 390 Alive
[19] 2008 IIIA C 39 M Ductopenia 501 157 1144 NIL 409 NR NR D: unknown
[4] 2008 IIIB CR 10 M Ductopenia 85 208 2434 Ductopenia NR NR NR D: unknown
[4] 2008 IIIB CR 12 M Ductopenia 184 151 NR NIL 433 NR NR Alive
This study 2010 IIA CT 38 M Ductopenia 252 53 155 DR 22 50 247 Alive
ALP Z alkaline phosphatase; AST Z aspartate aminotransferase; Bil Z bilirubin; C Z chemotherapy alone; CR Z chemotherapy þ radiotherapy;
CRSZ chemotherapy þ radiotherapy þ steroids; CTZ chemotherapy þ autologous hematopoietic cell transplantation; DZ died; DRZ ductal regeneration; FZ female; HDZ Hodgkin’s
disease; M Z male; Nil Z not performed; NR Z not reported in the article; NT Z no treatment for Hodgkin’s lymphoma as diagnosis was made after autopsy; R Z radiotherapy alone;
Tx Z treatment.
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Table 2 Summary of clinical features of 23 patients with
Hodgkin’s lymphoma-related vanishing bile duct syndrome.
Basic demographic
Age (y) (mean, range) 28 (3.5e54)
Gender (M:F) 18:5
Symptoms/signs (n/N, %)a
Jaundice 23/23 (100)
Pruritus 12/12 (100)
Weight loss 13/14 (93)
Night sweats 7/9 (78)
Fever 7/10 (70)
Neck lymphadenopathy 16/19 (84)
Hepatomegaly 8/16 (50)
Splenomegaly 6/18 (33)
Initial liver biochemical values (mean, range)
Aspartate transaminase (U/L) 152 (36e208)
Alkaline phosphatase (U/L) 960 (155e5724)
Total bilirubin (mmol/L) 305 (34e856)
Staging, treatment, and outcome
Stage (I/II/III/IV/NR) (n) (3/7/11/0/2)
Treatment
(C/R/CR/CS/CRS/CT/NT) (n)
(6/1/2/7/5/1/1)
CZ chemotherapy alone; CRZ chemotherapy þ radiotherapy;
CRS Z chemotherapy þ radiotherapy þ steroids;
CSZ chemotherapyþ steroid; CTZ chemotherapyþ autologous
hematopoietic cell transplantation; F Z female; M Z male;
NTZ no treatment; RZ radiotherapy alone.
a Percentage is expressed as the number of positive cases
divided by the number of total cases with definite record;
n Z number of positive cases; N Z total cases with definite
record.
640 K.-M. Wong et al.mean of 152 IU/L (range, 36e208 IU/L). Liver biopsies prior
to treatment were performed in 20 cases (Table 1); for
these cases, ductopenia was found in pathology. Three
cases did not receive liver biopsy prior to treatment. Two
received liver biopsy after chemotherapy treatment due to
persistent cholestasis [3,5]. The other case suffered from
VBDS at the remission stage of HL; therefore, liver biopsy
was performed after lymphoma had been treated [6].
Most of these cases were in Stage III (44%) and Stage II
(26%), which constituted 70% of all the cases (Table 2).
Thirteen percent of these patients were in Stage I, 4% in
Stage IV, 4% with relapsed disease, and 8% in unreported
stage. Treatments for these cases included chemotherapy
alone (26%); radiotherapy alone (4%); chemotherapy com-
bined with radiotherapy (8%); chemotherapy combined
with steroid (30%); a combination of chemotherapy, radio-
therapy, and steroid (22%); and no treatment as HL was
diagnosed by autopsy (4%). To the best of our knowledge,
our study is the first to demonstrate cases who received
autologous hematopoietic cell transplantation in addition
to chemotherapy for HL with a presentation of VBDS.
Autologous hematopoietic cell transplantation is consid-
ered a feasible treatment choice in such a rare case,
although its long-term benefit needs further observation.
After treatment, 44% of the cases survived. Survival cases
demonstrate apparent improvement of total bilirubin and
AST levels. The modest improvement of ALP levels in sur-
viving cases may be due to longer half-life of ALP and usageof steroid in some of the cases. Refractory response to
treatment for HL subsequently led to mortality in these
cases. Liver failure (42%) and sepsis (42%) were two main
causes of death. The remaining causes of death (16%),
however, were unidentifiable as death was sudden. As ex-
pected, fatal cases showed deterioration of total bilirubin,
AST, and ALP levels (Table 1).
Twelve cases had liver biopsies following treatment.
Among these, one case had repeated liver biopsy owing to
new liver nodules being found, which disclosed involvement
of the liver in Hodgkin’s disease [3]. Eight cases showed
persistent ductopenia and four of them met with mortality
due to sepsis, progressive liver failure, or HL [3e9]. Three
cases showed ductal regeneration and all remain alive to
date [[10,11], and this case] (Table 1).
Two possible mechanisms to explain HL-related VBDS
have been postulated: direct bile duct damage by infil-
trated lymphoma cells and paraneoplastic toxic cytokine
released by lymphoma cells [20]. The latter mechanism has
been accepted more due to the disparity between the
minor load of lymphoma and severe cholestasis seen in
those cases of HL-related VBDS and documented liver bi-
opsies prior to the initiation of chemotherapy [8,10,12,13].
The paraneoplastic effect may be related to mediators
released by inflammatory cells surrounding or infiltrating
the tumor [21,22]. In the past, patients with HD-related
VBDS were speculated to gain poor survival outcome, with
low regenerative capacity of injured bile ducts, leading to
irreversible damage, liver failure, and death [4]. Our re-
view gives pathological evidence to support the potential
reversibility of these diseases and survival in those cases
who respond to cancer treatment.
In conclusion, HL-related VBDS is a reversible paraneo-
plastic injury if the cancer responds to medical treatment.
Bilirubin is a more reliable cholestasis marker compared to
alkaline phosphatase in monitoring treatment response.
Autologous hematopoietic cell transplantation is a feasible
treatment of choice in such a rare case, although its long-
term benefit needs further observation.References
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